Abstract:BACKGROUND: Epigenetic alterations have been shown to contribute immensely to human carcinogenesis. Dynamic and reversible N6-methyladenosine (m6A) RNA modification regulates gene expression and cell fate. However, the reasons for activation of KIAA1429 (also known as VIRMA, an RNA methyltransferase) and its underlying mechanism in lung adenocarcinoma (LUAD) remain largely unexplored. In this study, we aimed to clarify the oncogenic role of KIAA1429 in the tumorigenesis of LUAD.METHODS: Whole-genome sequencing and transcriptome sequencing of LUAD data were used to analyze the gene amplification of RNA methyltransferase. The in vitro and in vivo functions of KIAA1429 were investigated. Transcriptome sequencing, methylated RNA immunoprecipitation sequencing (MeRIP-seq), m6A dot blot assays and RNA immunoprecipitation (RIP) were performed to confirm the modified gene mediated by KIAA1429. RNA stability assays were used to detect the half-life of the target gene.RESULTS: Copy number amplification drove higher expression of KIAA1429 in LUAD, which was correlated with poor overall survival. Manipulating the expression of KIAA1429 could regulate the proliferation and metastasis of LUAD. Mechanistically, the target genes of KIAA1429-mediated m6A modification were confirmed by transcriptome sequencing and MeRIP-seq assays. We also revealed that KIAA1429 could regulate BTG2 expression in an m6A-dependent manner. Knockdown of KIAA1429 significantly decreased the m6A levels of BTG2 mRNA, leading to enhanced YTH m6A RNA binding protein 2 (YTHDF2, the m6A "reader")-dependent BTG2 mRNA stability and promoted the expression of BTG2; thus, participating in the tumorigenesis of LUAD.CONCLUSIONS: Our data revealed the activation mechanism and important role of KIAA1429 in LUAD tumorigenesis, which may provide a novel view on the targeted molecular therapy of LUAD.

N6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy

The emerging roles of N6-methyladenosine RNA methylation in human cancers

M6a Methyltransferase KIAA1429 Acts As an Oncogenic Factor in Colorectal Cancer by Regulating SIRT1 in an M6a-Dependent Manner

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner

KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner

N6-methyladenosine modification: a novel pharmacological target for anti-cancer drug development

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3

N6-methyladenosine methyltransferase KIAA1429 elevates colorectal cancer aerobic glycolysis via HK2-dependent manner

Gene amplification‐driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A‐YTHDF2‐dependent in lung adenocarcinoma

KIAA1429 regulates cell proliferation by targeting c‐Jun messenger RNA directly in gastric cancer

N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

N6-methyladenosine links RNA metabolism to cancer progression

KIAA1429 promotes the malignancy of oral squamous cell carcinoma by regulating CA9 m6A methylation

Function of N6-Methyladenosine Modification in Tumors

Small Molecules that Regulate the N 6 -Methyladenosine RNA Modification as Potential Anti-Cancer Agents

M6a Modification: a New Avenue for Anti-Cancer Therapy

M6a Modification: A Double-Edged Sword in Tumor Development

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer